Singapore, Sept. 5 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pha... Read More
Singapore, Sept. 5 -- The Health Sciences Authority received information related to the study titled 'A Phase 1 randomized, double-blind, placebo-controlled, single-ascending-dose study investigating ... Read More
Singapore, Sept. 5 -- The Health Sciences Authority received information related to the study titled 'A Multinational, Multicenter Study With an Open-Label Phase 1b and a Randomized, Double-Blind, Pla... Read More
U.S., Sept. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07803783) titled 'A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients ... Read More
Singapore, Sept. 5 -- The Health Sciences Authority received information related to the study titled 'A multicenter, randomized, double-blind, placebo-controlled Phase 2 study to investigate the effic... Read More
Singapore, Sept. 5 -- The Health Sciences Authority received information related to the study titled 'A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Solut... Read More
Singapore, Sept. 5 -- The Health Sciences Authority received information related to the study titled 'RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib M... Read More
Singapore, Sept. 5 -- The Health Sciences Authority received information related to the study titled 'N-Acetylcysteine or Erdosteine for Exacerbations of Chronic Obstructive Pulmonary Disease (NEX COP... Read More
Singapore, Sept. 5 -- The Health Sciences Authority received information related to the study titled 'A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembr... Read More
Singapore, Sept. 5 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multicenter, Parallel-group Study to Eval... Read More